Elevated Donor-Derived Cell-Free DNA Correlates with Donor-Specific Antibodies and Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Patients Without Rejection.
Cell-free DNA markers may signal rejection risk and other kidney transplant issues beyond standard rejection indicators.
Donor-derived cell-free DNA (dd-cfDNA) is a biomarker used to screen for rejection, but its significance when elevated without rejection remains unclear in pediatric recipients. Donor-derived cell-free DNA levels may possess utility beyond screening for rejection.
What the study was
- Study design
- Retrospective study
- Population
- Cancer/disease patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Why it surfaced
Matched topic(s): Early cancer detection. Study design: Retrospective study. Score 5/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.